Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EC5026 in Neuropathic Pain due to Spinal Cord Injury
NCT06438471Phase 1Recruiting
- Sponsor
- EicOsis Human Health
- Start
- May 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in neuropathic pain comparing EC5026 with Placebo (2 arms). Primary endpoint: Incidence of Adverse Events and Serious Adverse Events at 30 days. Started May 2026; status: recruiting.
02
Drugs
EC5026
03
Conditions
neuropathic pain
Beyond the preview
Go deeper on NCT06438471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06438471.